

**ASX Announcement**

**18 November 2024**

## **OncoSil Signs Distribution Agreements for Nordics and Egypt**

**Sydney, Australia – 18 November 2024:** Pancreatic cancer treatment device company **OncoSil Medical Limited (ASX:OSL)** (“OncoSil” or “the Company”) is pleased to announce it has signed exclusive distribution agreements with CardiRad for the Nordics region and Femto Trade for Egypt.

CardiRad is a prominent distributor of innovative medical technologies in the Nordics, renowned for its strong expertise and extensive network in the fields of oncology and nuclear medicine. With this strategic agreement, CardiRad will be at the forefront of bringing OncoSil’s breakthrough technology to patients in Sweden, Denmark, Norway, and Finland, further enhancing cancer treatment capabilities in the region.

Femto Trade is a leading distributor of medical solutions in Egypt, specializing in nuclear medicine and interventional oncology. Their deep market reach, clinical knowledge, and established relationships with key medical institutions make them a valuable partner in delivering OncoSil’s transformative therapies to Egyptian patients.

**Nigel Lange, CEO & Managing Director of OncoSil Medical, said:**

*"Our agreements with CardiRad and Femto Trade reflect OncoSil's dedication to expanding access to our innovative brachytherapy treatment on a global scale. These partnerships mark an important step in our mission to provide life-changing care solutions to patients worldwide."*

### **Authorisation & Additional Information**

This announcement was authorised by the Chairman of OncoSil Medical Limited.

**For further information, please contact:**

<b>Mr. Nigel Lange</b> CEO & Managing Director E: <a href="mailto:nigel.lange@oncosil.com">nigel.lange@oncosil.com</a> T: +49 30 300 149 3043	<b>Mr. Christian Dal Cin</b> CFO & Company Secretary E: <a href="mailto:c.dalcin@acclime.com">c.dalcin@acclime.com</a> T: +61 3 9824 5254	<b>Ms. Julia Maguire</b> <b>The Capital Network</b> Media and Investor Enquiries E: <a href="mailto:julia@thecapitalnetwork.com.au">julia@thecapitalnetwork.com.au</a> T: +61 2 8999 3699
--------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**About OncoSil Medical**

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12<sup>th</sup> most common cancer in men and the 11<sup>th</sup> most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival<sup>1</sup>.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (<sup>32</sup>P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient's pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: [www.oncosil.com/](http://www.oncosil.com/)

**References:** 1. <https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/>